Carcinoma, Hepatocellular: all 3,251 studies

Page 22 of 33. Open to participants first (976), then studies with results posted, then the rest; newest registration first within each.

• The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular CarcinomaStatus unknownNCT03917017Not applicable
• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingNCT03916627Phase 2
• A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic ResectionStatus unknownNCT03914352Not applicable
• TILA-TACE in Treatment of Hepatocellular CarcinomaStatus unknownNCT03910140Not applicable
• Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular CarcinomaStatus unknownNCT03908840Phase 1
• Branched-chain Amino Acid Supplementation for Hepatocellular CarcinomaWithdrawnNCT03908255Phase 2
• TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCCStatus unknownNCT03905967Phase 3
• Application of Watson for Oncology in Hepatocellular Carcinoma SurgeryStatus unknownNCT03904667
• Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular CarcinomaStatus unknownNCT03902678Not applicable
• TCR-Redirected T Cells Therapy in Patient With HBV Related HCCStatus unknownNCT03899415Phase 1
• RFA vs. SBRT for Small HCCStatus unknownNCT03898921Phase 3
• Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)Active, not recruitingNCT03896646Not applicable
• Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedNCT03893695Phase 1/2
• Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular CarcinomaStatus unknownNCT03892681Not applicable
• ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular CarcinomaCompletedNCT03888859Early Phase 1
• Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Phase 1
• Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular CarcinomaStatus unknownNCT03881501
• By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave AblationStatus unknownNCT03880721
• Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular CarcinomaActive, not recruitingNCT03878550
• Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC PatientsStatus unknownNCT03869151
• HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCCActive, not recruitingNCT03869034Phase 2
• Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaTerminatedNCT03867370Phase 1/2
• Thermal Ablation Followed by Immunotherapy for HCCStatus unknownNCT03864211Phase 1/2
• Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Phase 2/3
• Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular CarcinomaStatus unknownNCT03857815Phase 2
• Probiotics in the Prevention of Hepatocellular Carcinoma in CirrhosisStatus unknownNCT03853928Not applicable
• Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)CompletedNCT03852238
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03851939Phase 2
• The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent HepatectomyStatus unknownNCT03851913Phase 3
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)Status unknownNCT03851887Phase 2
• Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular CarcinomaCompletedNCT03851471Early Phase 1
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
• Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2
• Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver TransplantationActive, not recruitingNCT03839706Not applicable
• Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
• Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaStatus unknownNCT03838796Not applicable
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 2
• A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 1
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
• Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal CancerCompletedNCT03819088Not applicable
• A Study of PTX-9908 Injection for Non-resectable HCC With TACEWithdrawnNCT03812874Phase 1/2
• HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCCStatus unknownNCT03812783Phase 2
• Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCCStatus unknownNCT03812770Phase 2
• Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1
• A Study on the Angioarchitecture of Hepatocellular CarcinomaTerminatedNCT03808766Not applicable
• Radial Versus Femoral Access for Superselective Embolization of Hepatocellular CarcinomaStatus unknownNCT03807947Not applicable
• Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCCCompletedNCT03806218Not applicable
• HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)CompletedNCT03804593
• HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCCWithdrawnNCT03803254Phase 2
• A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Status unknownNCT03794440Phase 2/3
• A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCCStatus unknownNCT03793725Phase 2
• The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular CarcinomaStatus unknownNCT03793322Phase 1
• Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
• Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.Status unknownNCT03790059Not applicable
• TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCCWithdrawnNCT03782831Phase 2
• A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
• A Study to Evaluate MIV-818 in Patients With Liver Cancer ManifestationsCompletedNCT03781934Phase 1/2
• HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCCWithdrawnNCT03780634Phase 2
• HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-BStatus unknownNCT03780049Phase 3
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
• the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03777475Not applicable
• AFP Model and Liver Transplantation.CompletedNCT03775863
• Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.Status unknownNCT03775798
• Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2
• HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3
• Yliver as a Test to Early Diagnose HCCCompletedNCT03767764
• Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03766776Not applicable
• Harms of Hepatocellular Carcinoma SurveillanceCompletedNCT03756051
• Perfusion and Dual Energy Computer Tomography in Hepatocellular CarcinomaStatus unknownNCT03754192Not applicable
• Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaWithdrawnNCT03748927
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
• Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Phase 3
• Evaluation of Diagnostic Accuracy of CEUS for HCC DiagnosisStatus unknownNCT03742453Not applicable
• Study of TG02 Citrate in Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT03738111Phase 1
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
• Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCCStatus unknownNCT03734068
• Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular CarcinomaStatus unknownNCT03732547Phase 2
• Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TAREStatus unknownNCT03731910Not applicable
• Irradiation Stent Placement Plus TACE for HCC and PVTTStatus unknownNCT03730675Not applicable
• Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol EmulsionTerminatedNCT03727633Phase 2
• SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Not applicable
• The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LCStatus unknownNCT03722628
• Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACEWithdrawnNCT03722498Phase 2
• Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic SurgeryStatus unknownNCT03718078Not applicable
• Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective StudyStatus unknownNCT03708705
• Direct Acting Antiviral-Post Authorization Safety StudyCompletedNCT03707080
• Hepatocellular Carcinoma in HIV-infected Individuals in Asian PopulationCompletedNCT03702998
• Dual and Single Switching Monopolar RFA Using Separable Clustered Electrode for Treatment of HCCCompletedNCT03699657Not applicable
• TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruitingNCT03680508Phase 2
• A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular CarcinomaCompletedNCT03674073Phase 1
• Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCCStatus unknownNCT03672305Early Phase 1
• Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular CarcinomaStatus unknownNCT03668158
• A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular CarcinomaCompletedNCT03663114
• Ablative Chemoembolization for Unresectable and Large Hepatocellular CarcinomaTerminatedNCT03662841Not applicable
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1
• Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated CirrhosisActive, not recruitingNCT03654053Phase 3
• Anatomy-based Resection or Margin-based Resection for Hepatocellular CarcinomaStatus unknownNCT03652896Not applicable
• The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular CarcinomaStatus unknownNCT03652467Phase 1
• DKN-01 Inhibition in Advanced Liver CancerStatus unknownNCT03645980Phase 1/2
• Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line TreatmentTerminatedNCT03644511

← Carcinoma, Hepatocellular overview